Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

Antonia Carroll, P James Dyck, Mamede de Carvalho, Marina Kennerson, Mary M Reilly, Matthew C Kiernan, Steve Vucic

ABSTRACT
Hereditary transthyretin amyloidosis (ATTRv) is a severe, adult-onset autosomal dominant inherited systemic disease predominantly affecting the peripheral and autonomic nervous system, heart, kidney and the eyes. ATTRv is caused by mutations of the transthyretin (TTR) gene, leading to extracellular deposition of amyloid fibrils in multiple organs including the peripheral nervous system. Typically, the neuropathy associated with ATTRv is characterised by a rapidly progressive and disabling sensorimotor axonal neuropathy with early small-fibre involvement. Carpal tunnel syndrome and cardiac dysfunction frequently coexist as part of the ATTRv phenotype. Although awareness of ATTRv polyneuropathy among neurologists has increased, the rate of misdiagnosis remains high, resulting in significant diagnostic delays and accrued disability. A timely and definitive diagnosis is important, given the emergence of effective therapies which have revolutionised the management of transthyretin amyloidosis. TTR protein stabilisers such as diflunisal and tafamidis can delay the progression of the disease, if treated early in the course. Additionally, TTR gene silencing medications, patisiran and inotersen, have resulted in up to 80% reduction in TTR production, leading to stabilisation or slight improvement of peripheral neuropathy and cardiac dysfunction, as well as improvement in quality of life and functional outcomes. The considerable therapeutic advances have raised additional challenges, including optimisation of diagnostic techniques and management approaches in ATTRv neuropathy. This review highlights the key advances in the diagnostic techniques, current and emerging management strategies, and biomarker development for disease progression in ATTRv.

INTRODUCTION
Amyloidoses refer to a heterogeneous group of diseases that are pathologically characterised by aggregation of amyloid-fibril proteins deposited extracellularly, resulting in a toxic gain of function.1 In accordance with the official amyloid fibril protein nomenclature list published by the International Society of Amyloidosis, 36 amyloid fibril proteins are known to cause amyloidosis, with diseases classified according to the nature of the amyloid precursor protein.2 Transthyretin (TTR) is a human 55 kDa transport protein that is predominently synthesised by the liver and secreted into the bloodstream. The main physiological function of TTR is to transport retinol-binding protein–vitamin A complex (holoRBP) and thyroxine (T4). TTR has a tetrameric structure composed of four identical beta-sheet rich subunits with two T4 and four holoRBP-binding sites.3 Studies of TTR knockout (TTR-KO) mice have reported sensorimotor dysfunction and impairment of nerve recovery in response to crush injuries.4 Expression of human TTR in TTR-KO mice rescued the phenotype, reinforcing the importance of TTR in nerve repair.3 A neuroprotective role for TTR in the central nervous system (CNS) has also been reported.5 TTR is synthesised by the choroid plexus, retinal pigment epithelium and pancreas,2 where it may contribute to a variety of physiological functions including transport of thyroid hormones.

GENETICS OF ATTRv
ATTRv encompasses a range of phenotypes (figure 1), with autosomal dominant pattern of inheritance. To date, 140 different TTR mutations

To cite: Carroll A, Dyck PI, de Carvalho M, et al. J Neurol Neurosurg Psychiatry 2022;0:1–11. doi:10.1136/jnnp-2021-327909

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Received 25 November 2021
Accepted 12 February 2022
have been reported, with the Val30Met (p.Val30Met) variant being the most frequent. The Val30Met mutation is responsible for high prevalence of ATTRv in endemic areas, including Portugal (incidence 0.87/100 000, prevalence 22.9/100 000), Sweden and Japan. The carrier frequency in the Swedish population is high (~1.5%), with evidence of anticipation (~11.7 years). The risk of anticipation was higher in males and with maternal transmission. In non-endemic regions, the carrier frequency of the Val30Met variant is lower. Carrier frequency markedly varies between racial backgrounds, as underscored by the frequent occurrence of the ATTRv Val122Ile (p.Val142Ile) mutation in Afro-American, West African and Hispanic populations. Distinct founder mutations have been reported in other regions, including the Thr60Ala (p.Thr80Ala) TTR variant in northwest Ireland, and THE Ala97Ser (p.Ala117Ser) variant in China and Taiwan. Although different TTR mutations may result in phenotypic overlap, mutations causing predominantly neuropathic, cardiomyopathic or mixed phenotypes have been reported (figure 1). Early-onset Val30Met mutations present with peripheral neuropathy, while Thr60Ala variants often manifest as mixed neuropathic and cardiomyopathic phenotypes. In contrast, the Val122Ile variant presents with late-onset disease with predominant cardiac dysfunction. Phenotype heterogeneity has been reported for the same mutations, both across different pedigrees and within familial groups. Variability in age of disease onset has been reported, with the best predictor being onset age within the family pedigree. Although ATTRv exhibits an autosomal dominant pattern of inheritance, incomplete penetrance has been described, with different mutations and populations exhibiting varied penetrance rates. While penetrance can be difficult to ascertain for late-onset variants, early-onset phenotypes (Val30Met) have a penetrance of 80% at 50 years and 91% at 70 years in Portuguese, compared with 15% at 50 years in Swedish patients. The interaction between carrier frequency, age of onset and penetrance determines population prevalence of ATTRv. While the Val30Met carrier frequency in Portugal is low, the high penetrance and early age of onset result in a high population prevalence.

**CLINICAL SPECTRUM OF ATTRv PHENOTYPE**

ATTRv amyloidosis is a multisystem disease as summarised in figure 1A. Understanding the clinical spectrum of ATTRv will raise suspicion and thereby enable early diagnosis of ATTRv, allowing the institution of effective therapies.

**Hereditary transthyretin amyloidosis–polyneuropathy**

ATTRv-PN is the most common of the amyloid phenotypes and most frequently associated with the Val30Met mutation. Early-onset ATTRv-PN phenotype is common in Portugal and Japan, characterised by onset at <50 years, high penetrance and
progressive axonal length-dependent sensorimotor polyneuropathy. Small-fibre neuropathy is also frequently reported, characterised by loss of nociception and thermal sensation, burning feet and paresthesias in distal lower extremities. Autonomic neuropathy (AN) occurs in ~75% of patients with ATTRv, characterised by orthostatic hypotension (light-headedness, exercise intolerance and non-specific fatigue), gastrointestinal (gastroperesis, recurrent vomiting, diarrhea or alternating diarrhoea–constipation and faecal incontinence) and genitourinary (urinary retention, nocturia, incomplete emptying and frequency, and erectile dysfunction) symptoms. Autonomic symptoms may be disabling, with high morbidity from arrhythmias and sudden death. Malnutrition and weight loss may ensue, which are adverse prognostic factors. Amyloid deposition in the bowel wall may contribute to gastrointestinal symptoms. Cardiac conduction defects appear frequently, requiring pacemaker implantation, along with myocardial thickening. Late-onset ATTRv-CM begins at >50 years of age and occurs in endemic and non-endemic regions. Clinically, it is characterised by progressive axonal sensorimotor neuropathy affecting all sensory modalities, variable penetrance, lack of family history and milder AN symptoms. Neuropathic pain is more frequent than in early-onset ATTRv, particularly with the Thr60Ala variant. Upper limb-onset axonal neuropathy has also been reported, as have gastrointestinal symptoms. Upper limb-onset axonal neuropathy has also been reported, as have gait ataxia with large-fibre sensory loss, paucity of muscle weakness and generalised areflexia. ATTRv-CM may be misdiagnosed as chronic inflammatory polyradiculoneuropathy, with slowing of motor conduction velocities in the demyelinating range, elevated cerebrospinal fluid (CSF) protein, and paucity of autonomic and systemic involvement. A pure motor syndrome with absence of AN has also been observed in non-Val30Met variants. Amyloid cardiomyopathy and gastrointestinal dysfunction are frequently observed in late-onset ATTRv.

Bilateral carpal tunnel syndrome (CTS) frequently occurs in early-onset and late-onset ATTRv-PN and ATTRwt, commonly preceding other organ involvement by years (Rukavina type). Other neuromuscular manifestations include myopathy, exhibiting a limb or axial pattern of muscle weakness, mildly elevated creatine kinase levels, absence of dysphagia and presence of systemic features. Spinal canal stenosis is also a feature of transthyretin amyloidosis (ATTR) due to amyloid deposition in the ligamentum flavum, resulting in neurogenic claudication.

Hereditary transthyretin amyloidosis–cardiomyopathy
ATTRv-CM is evident in ~50% of patients, and while frequently associated with Val122Ile (~3% to 4% of African-Americans) and Ile111Met (p.Ile131Met) TTR variants, other mutations are more common in Caucasian, Hispanic and Asian populations. ATTRv-CM is more common in late-onset (Val30Met) ATTRv, manifesting as restrictive cardiac failure, otherwise known as heart failure with preserved ejection fraction (HFpEF), conduction blocks, ventricular arrhythmias or sudden cardiac death. ATTRv-CM is indistinguishable by clinical findings or investigation characteristics from ATTRwt–cardiomyopathy. Low-voltage ECG or pseudo-infarct patterns in right praeordial leads are consistent with ATTR-CM. Myocardial thickening, along with subendocardial late gadolinium enhancement, is a characteristic cardiac MRI feature. Echocardiography demonstrates thickened septal and ventricular walls, impaired diastolic relaxation and reduced global longitudinal strain with an apical sparing pattern. Additionally, 99mTc-phyrophosphate (PYP), 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) or 99mTc-hexamethylene diphosphonate (HMDP) scintigraphy is considered the most sensitive for detecting amyloid deposition in ATTR-CM. Myocardial sympathetic denervation, measured by 123-iodine metaiodobenzylguanidine imaging, is an independent predictor of mortality and represents the importance of autonomic changes in ATTR-CM. ATTRv-CM is associated with increased mortality and is the major cause of death in non-endemic regions.

Leptomeningeal amyloidosis
ATTRv-LA is a rare manifestation of ATTRv, most frequently associated with non-Val30Met mutations (Leu12Pro, Ala25Thr, Gly53Glu, Tyr114Cys, Asp18Gly or Tyr69His). Pathologically, ATTRv-LA is characterised by cerebral amyloid angiopathy and leptomeningeal amyloidosis. Amyloid deposits may be evident in the media and adventitia of medium-sized and small-sized cortical arteries, arterioles and veins, as well as veins in the subarachnoid space and leptomeninges. In the CNS, the choroid plexus is the main source of amyloid. Ischaemic strokes and intracerebral haemorrhage, along with subarachnoid haemorrhage and hydrocephalus, are common complications. Symptoms include headaches, hearing or visual loss, cerebral haemorrhages, dementia, ataxia, spasticity, transient focal neurological episodes (amyloid spells) and seizures. Neurpathy is an inconsistent feature of ATTRv-LA. Separately, ATTRv-LA may be evident in patients with the Val30Met mutation, typically 11 years after liver transplantation, due to ongoing variant TTR production by the choroid plexus. Age-related cognitive dysfunction was reported in older patients with ATTRv (>50 years) with Val30Met, implying the pathogenic importance of centrally produced TTR variant protein. Cranial nerves can be affected, mimicking amyotrophic lateral sclerosis.

Other organ involvement in ATTRv
Renal disease, manifesting as proteinuria, nephrotic syndrome and progressive renal failure, occurs in one-third of Portuguese patients (Val30Met), most commonly evident in the late-onset phenotype. Microalbuminuria can be the first abnormality, and 10% develop end-stage renal disease secondary to vascular and glomerular amyloid depositions. Ocular involvement, manifesting as dry eyes and keratoconjunctivitis, vitreous opacity due to amyloid deposition, cataracts, secondary open-angle glaucoma and retinal amyloid angitis may be evident in up to 25% of patients with ATTRv typically evident with Val30Met mutations. Gastrointestinal symptoms result from both AN and direct deposition of amyloid in the bowel wall, leading to small intestinal bacteria overgrowth (blind-loop phenomenon).

WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS
ATTRwt, previously known as senile systemic amyloidosis, is a common disease of ageing, with autopsy studies disclosing that 10%–25% of over 80-year-olds had wild-type amyloid deposition in the myocardium, and 44% in the gastrointestinal tract and subcutaneous tissue. A significant burden of amyloid deposition is required to cause symptomatic disease, and hence, histopathological deposition does not necessarily equate to clinical significance. ATTRwt presents between the sixth-eighth decades of life, manifesting as HFpEF, atrial fibrillation and ventricular arrhythmias, occasionally requiring implantation of a cardioverter defibrillator. CTS is a common presenting feature, as is spinal canal stenosis, while other systemic manifestations are less frequent.
Additionally, CNFL has no floor effect when compared with fibril typing is essential, preferably by mass spectrometry (figure 3). In cases where pathological TTR mutations coexist with monoclonal gammopathy with a sensitivity of 80% in cases where immunohistochemical staining was unrevealing.50

Skin biopsy may be of utility in early diagnosis of neuropathy, disclosing reduced intraepidermal nerve fibre density and Congo red positive amyloid deposits.48 Confocal corneal microscopy is an emerging technique for detecting small-fibre neuropathy and represents a non-invasive alternative. Corneal nerve fibre length (CNFL) is shorter in ATTRv and correlates with autonomic, clinical and neurophysiological measures of large-fibre neuropathy.49 Additionally, CNFL has no floor effect when compared with neurophysiological testing and intraepidermal nerve fibre density measurements.

Identification of a TTR gene mutation is strongly suggestive of ATTRv if the neurological phenotype and investigations are concordant, including positive cardiac uptake on 99m Tc-PYP, 99m Tc-DPD or HMDP scintigraphy with negative monoclonal gammopathy and general neuropathy screen (figure 3). TTR mutations can be excluded or established on genetic testing, as sequence analysis identifies >99% of pathogenic variants, with updated lists of TTR mutations and phenotypes reported in an online database (http://www.amyloidosismutations.com/mut-attr.php). Diagnostic practices may vary across countries, and pathological diagnosis remains the gold standard. Genetic testing is required to differentiate between ATTRwt and ATTRv.

Once amyloid deposition is confirmed histologically, amyloid protein typing is essential to guide management. Immunohistochemical stains can be used, although amyloid precursor protein typing is essential, preferably by mass spectrometry (figure 3).51 Consequently, non-biopsy diagnosis of ATTR-CM amyloidosis is now possible when there is considerable cardiac bone scintigraphy uptake (grade 2 or 3) and absence of monoclonal protein (figure 3). In cases where pathological TTR mutations coexist with monoclonal amyloidosis with high sensitivity, specificity and positive predictive value (>99%) when there is no concurrent monoclonal gammopathy on serum and urine electrophoresis or immunofixation, and in the absence of serum-free light chains.51

99m Tc-PYP and 99m Tc-DPD scintigraphy (figure 2D,E) demonstrate ATTR amyloid deposition in the myocardium with high sensitivity, specificity and positive predictive value (>99%) when there is no concurrent monoclonal gammopathy on serum and urine electrophoresis or immunofixation, and in the absence of serum-free light chains.51

Plasma neurofilament light chain (NfL) is emerging as a useful prognostic biomarker in ATTR-PN, demonstrating a fourfold increase and correlating with disease severity.52 53 54 55 NfL may discriminate between asymptomatic Val30Met mutation carriers and ATTR-PN in early disease.56 A significant reduction of NfL levels...
was reported in patients with ATTR-PN treated with gene silencing therapies, correlating with an improvement in the neuropathy impairment score.54

**Diagnostic approach for ATTR neuropathy**

A putative diagnostic algorithm for ATTR-PN is depicted in figure 3. In all patients presenting with polyneuropathy, particularly with small fibre or AN, we recommend a review of amyloid red flag symptoms, such as the presence of bilateral CTS, cardiomyopathy or pacemaker insertion, along with consideration of ethnicity and family history (figure 3). It is essential to consider amyloidosis in these scenarios to shorten diagnostic delays and prevent misdiagnosis. As ATTRv is now treatable, we suggest a low threshold for early TTR gene testing (figure 3). If a TTR gene variant is detected in cases with no family history, a tissue diagnosis is required. Practice varies across countries and with different phenotypical expression, but may include abdominal fat pad aspirate, skin, salivary gland, nerve or other target organ biopsies. Amyloid protein typing by immunohistochemistry or preferably laser dissection–mass spectrometry is critical, particularly in the setting of a coincidental paraprotein (figure 3). Occasionally, amyloid is identified incidentally on a diagnostic nerve biopsy. In this circumstance, typing of the amyloid fibril is critical, as while more commonly AL, ATTRv is a possibility and should prompt gene testing. If local laboratories are not able to confidently type the fibril, we recommend that tissue be referred to a specialised laboratory for fibril typing. Early gene testing may help to guide testing and improve time to diagnosis.

In an individual with typical neuropathy and biopsy-proven family history of ATTRv, gene testing should be performed as an initial investigation (figure 3). If a TTR variant is identified, a 99mTc-DPD or 99mTc-PYP bone scan may be performed as the next diagnostic investigation. ATTR may be diagnosed without the need for tissue biopsy, if grade 2 or 3 scintigraphic uptake abnormalities are identified and if echocardiographic/cardiac MRI criteria are satisfied, and a paraprotein is not identified on complete monoclonal gammopathy testing (serum and urine electrophoresis, immunofixation and serum-free light chains). For many clinical trials and medicine regulators, biopsy confirmation may be required. If bone scintigraphy, echocardiogram or cardiac MRI criteria are not met, tissue biopsy is required for diagnosis (figure 3). TTR gene mutations may coexist with other neuropathy-causing diseases, especially in older patients, such as diabetes mellitus, and in this circumstance, a nerve biopsy should be considered to confirm that the neuropathy is secondary to amyloidosis. It should be stressed that additional diagnostic approaches have been proposed and are discussed in detail elsewhere.55

**PATHOGENESIS OF ATTRV**

**TTR amyloid fibril formation**

The conversion of TTR tetramer into insoluble amyloid fibrils is a multistep dynamic process (figure 4). Dissociation of TTR tetramer into misfolded monomers appears to be a rate-limiting step for formation of amyloid fibrils and other aggregate morphologies.5 TTR gene mutations destabilise quaternary and tertiary TTR structures and induce thermodynamic instability, thereby favouring

---

*Note: May require tissue biopsy to meet eligibility requirements for clinical trials or medicine regulations.*

*Figure 3* Diagnostic algorithm for ATTR polyneuropathy. Tissue biopsy may include a target organ such as nerve, heart, bone marrow or skin, or an ‘off-target’ biopsy such as salivary gland or abdominal fat pad aspirate. Depending on availability, IHC and LD-MS are important for amyloid fibril typing. Bone scintigraphy may be semiquantitatively graded relative to rib uptake with the following grades: grade 0, no uptake and normal bone scan; grade 1, uptake less than rib uptake; grade 2, uptake equal to rib uptake; and grade 3, uptake greater than rib uptake with mild or absent rib uptake abnormalities. Echo and CMR are important investigations for detecting cardiac amyloid disease. ATTR, transthyretin amyloidosis; ATTR-PN, transthyretin amyloidosis–polyneuropathy; CMR, cardiac MRI; CTS, carpal tunnel syndrome; Echo, echocardiogram; IHC, immunohistochemistry; LD-MS, laser dissection–mass spectrometry; MGUS, monoclonal gammopathy of uncertain significance; TTR, transthyretin.
Neuromuscular

Figure 4  Mechanisms by which TTR mutants exert pathogenesis and therapeutic strategies for ATTRv. TTR is predominantly produced by the liver. The conversion of TTR tetramer into insoluble amyloid fibrils is a multistep dynamic process, with dissociation of TTR tetramers into misfolded monomers being the rate-limiting step for the formation of amyloid fibrils. TTR gene mutations destabilise quaternary and tertiary TTR structures and induce thermodynamic instability, resulting in the formation of misfolded monomers. Amyloid fibril formation occurs by nucleation-dependent polymerisation and is influenced by a variety of physiological factors. Therapeutic strategies aimed at different stages of amyloid formation have shown efficacy in ATTRv. ATTRv, hereditary transthyretin amyloidosis; TTR, transthyretin.

Toxicity of amyloid fibrils

Amyloid fibrils may cause tissue damage by compression, obstruction, cellular toxicity or disturbance of local blood circulation. Vascular deposition may be a pathological feature of systemic amyloidosis, resulting in atypical amyloid presentations, such as jaw claudication and myocardial ischaemia in the absence of atherosclerotic disease. Cellular toxicity is mediated by low-molecular weight oligomers and protofibrils, by activation of the receptor for advanced glycation end products, resulting in endoplasmic reticulum stress, caspase-dependent apoptosis and activation of extracellular signal-regulated kinases with disruption of cellular differentiation. Induction of calcium influx and increased oxidative stress represent additional pathogenic mechanisms by which oligomers and protofibrils exert toxic effects. Furthermore, direct fibril ultrastructural damage has been identified by a recent electron microscopic study which demonstrated amyloid fibril maturation from prefibrillar and rounded structures arising within the amorphous extracellular material. Fibril maturation resulted in distortion of the surrounding Schwann cell basement and cytosolic membranes, leading to atrophy of Schwann cells.

DISEASE-MODIFYING THERAPIES FOR ATTRV

Strategies for treating ATTRv are directed at reducing the production and deposition of the pathogenic TTR. The following therapeutic approaches have shown efficacy: (1) targeting of TTR production, (2) stabilisation of TTR tetramers and (3) degradation of TTR amyloid deposits. Online supplemental table 1 provides a summary of clinical trials in ATTRv.

Liver transplantation

Liver transplantation is effective at ameliorating the course of ATTRv by replacing the mutated TTR gene with wild type, resulting in marked reduction of variant TTR serum concentrations and regression of amyloid deposition. The survival rates of 5 and 10 years are 83% and 73%, respectively, with greater effects evident in Val30Met ATTR-PN. Early-onset disease, shorter disease duration, better nutritional status prior to transplantation and improved perioperative management have been associated with improved survival. No significant effects were reported in late-onset disease ATTRv, although women with late-onset disease had a longer survival. The outcome of patients who receive liver transplantation...

formation of misfolded monomers. These destabilising effects impact the cell’s efficiency at degrading and secreting mutant TTR, thereby modifying disease severity. However, it must be noted that TTR amyloid deposition can occur without destabilising mutations, as is observed in ATTRwt. Further, wild-type TTR is frequently identified in amyloid deposits in patients with ATTRv, in particular in late-onset ATTRv30M cases and in cardiac tissues after liver transplantation. Amyloid fibril formation occurs by nucleation-dependent polymerisation, whereby formation of the oligomeric high-energy quaternary structures is required prior to aggregation of misfolded monomers. Subsequently, deposition of TTR monomers proceeds by spontaneous downhill polymerisation, and C-terminal TTR protein fragments produced by trypsin proteolysis are likely to promote TTR aggregation. The formation of amyloid fibrils is influenced by several factors including temperature, pH, presence of cosolvent precursor protein concentration, abnormal proteolysis and proteostatic mechanisms, oxidative stress, shear stress, pH alterations and interactions with extracellular matrix components, such as sulfated glycosaminoglycans.
after liver transplantation is better for live compared with cadaveric donor grafts. Liver transplantation is associated with improvement or stabilisation in peripheral neuropathy and AN. While liver transplantation is an accepted therapeutic option, limitations include procedure-related morbidity and mortality (~10%), requirement for donors and long-term immunosuppression, along with lack of equivalent efficacy for non-Val30Met ATTRs. Liver transplantation fails to reduce TTR production in the choroid plexus and retinal pigment cells, potentially leading to development of oculoleptomeningeal disease. Domino-liver transplantation was used to overcome organ shortage, but recipients developed polyneuropathy about 10 years after intervention. Nowadays, liver transplantation could be considered in patients refractory or intolerant to other pharmacological options, or when other treatment options are unavailable.

**TTR TETRAMER STABILISERS**

**Diffunisal**

Diffunisal is an oral non-steroidal anti-inflammatory drug that inhibits amyloid fibril formation by binding to the T4 binding sites of TTR protein. Diffunisal led to stabilisation of variant TTR tetramer and reduction of protein aggregation. A phase III trial demonstrated efficacy of diffunisal (250 mg two times per day) in ATTRv-PN (Val30Met and non-Val30Met mutations), with sustained slowing of neuropathy progression and improvement in quality of life.

A long-term open-label study demonstrated stabilisation in peripheral neuropathy, although the alteration in rate of decline was not significant. Separately, cardiac dysfunction was reduced by diffunisal. Significant side effects were reported, including gastrointestinal symptoms and transitory renal function impairment.

**Tafamidis**

Tafamidis is an oral TTR-tetramer protein stabiliser which reduces TTR–variant protein aggregation by associating with the T4 binding site. While tafamidis failed to meet the coprimary endpoints (Neuropathy Impairment Score–Lower Limbs (NIS-LL) and Norfolk Quality of Life–Diabetic Neuropathy (QOL-DN) total scores), a greater proportion of tafamidis-treated patients were classified as NIS-LL responders and reported preserved total quality of life (TQOL), suggesting clinical efficacy. An open-label extension study disclosed stabilisation of NIS-LL and TQOL scores, with greater preservation of neurological function in patients initiated at earlier stages of disease progression. The clinical benefit was associated with stabilisation of plasma TTR levels. Efficacy and safety of tafamidis was also reported in a small cohort of Japanese patients with ATTRv (Val30Met and non-Val30Met mutations). A long-term extension study in mild ATTRv-PN reported a sustained delay in neuropathy progression and long-term preservation of nutritional status. No clinical effects were evident in patients with ATTRv with advanced disease. Tafamidis reduced mortality risk in early (91%) and late (82%) affected patients compared with untreated patients. Greater baseline neurological dysfunction appears to be an independent predictor of disease progression, and early treatment was associated with slower rates of disease progression. The European medicine agency approved tafamidis in 2011 for stage 1 ATTRv, although 30%–40% of the patients were considered non-responders.

A recent multicentre phase III trial established efficacy of tafamidis in ATTR-CM, with lower mortality, cardiovascular-related hospitalisations, improved quality of life and functional capacity. A subsequent long-term study reaffirmed the clinical effectiveness. Tafamidis was approved in 2020 for treating ATTRwt and ATTRv-related cardiomyopathy.

**OTHER TTR STABILISERS**

**Acoramid**

AG10 is a novel and selective oral TTR stabiliser developed for treatment of ATTR. Recent studies demonstrated the safety and biological efficacy of AG10. Currently, phase III trials are assessing the effectiveness of AG10 in ATTR-CM (NCT03860935) and ATTR-PN (NCT04882735).

Green tea extract, which contains the catechin epigallocatechin-3-gallate (EGCG), is an inhibitor of amyloid fibril formation and disrupts fibril aggregation. Orally administered EGCG was associated with stabilisation of cardiac function in ATTRv amyloidosis. Utility of EGCG in ATTRv neuropathy remains unresolved, although high CNS bioavailability makes this an interesting target for potential multidrug therapies. Tolcapone, a TTR stabiliser that effectively crosses the blood–brain barrier, is being investigated as a potential treatment for ATTRv-LA.

**TTR FIBRIL REMOVAL**

Combination therapy with doxycycline, which interferes with formation of TTR amyloid fibrils, and tauroursodeoxycholic acid (TUDCA), a biliary acid that reduces non-fibrillar TTR aggregation, was reported to exert synergistic effect in the TTR mouse model (Val30Met). Stabilisation of neurological and cardiac function over 12 months was reported by combining doxycycline (200 mg/day) and TUDCA (250 mg three times per day). Monoclonal antibodies developed against serum amyloid P (SAP) (constituent that contributes to aggregate stability) and TTR (including PRX004) have disclosed mixed results. While initial murine and human studies of anti-SAP led to clearance of amyloid tissue deposits, ongoing clinical trials have been suspended. A recent small phase I trial of PRX004 demonstrated safety and tolerability of anti-TTR treatment while reducing progression of neuropathy and cardiac disease (https://ir.prothena.com/static-files/ee65ab75-2e8b-4eae-989b-3de7c7bd9149). Phase II studies of anti-TTR monoclonal antibodies are ongoing.

**GENE THERAPIES**

Gene silencing therapies using antisense oligonucleotides (ASOs) or siRNAs have emerged as safe and effective strategies for treating ATTR. The two main gene silencing compounds that have undergone extensive clinical assessment in ATTR include inotersen (ASO) and patisiran (siRNA) and have been approved for treating stage 1 and 2 ATTRv.

**Antisense oligonucleotides**

Inotersen is a short ASO that selectively binds to the complementary RNA, preventing RNA translation and protein expression. Preclinical studies established that TTR-specific ASOs suppress production of TTR mRNA by hepatocytes, with reduction of serum TTR protein levels in transgenic mouse models (Ile84Ser). Subsequently, an ASO (ISIS-TTRm) binding to the 3’ non-translated portion of the human TTR mRNA was developed and shown to significantly decrease liver mRNA and plasma TTR protein levels in animal models. A first in human phase I clinical trial established the safety and biological efficacy of ISIS-TTRmx.

Carroll A, et al. J Neurol Neurosurg Psychiatry 2022;0:1–11. doi:10.1136/jnnp-2021-327909
The pivotal phase III (NEURO-TTR) study established efficacy of inotersen (300 mg/week) in adult-onset patients with stage 1 (ambulatory) and stage 2 (ambulatory with assistance) ATTRv-PN.93 The decline in modified NIS+7 (mNIS+7) and Norfolk QOL-DN were significantly reduced by inotersen, and effectiveness was independent of disease stage, TTR mutation or presence of cardiomyopathy. Thrombocytopenia and glomerulonephritis were evident in 3% of patients. An open-label extension study confirmed clinical effectiveness of inotersen, including in patients switching from placebo,96,97 associated with significant reductions in serum TTR levels.95,97

Additional analysis of the NEURO-TTR trial revealed stabilisation or improvement in sensory, motor and autonomic symptoms.98 Analysis of modified NIS+7 components and lower limb function revealed effects on muscles weakness, sensation and heat pain perception as well as lower limb reflexes.99 Improvement in lower limb function and summated mNIS+7 neurophysiological subscores (five nerves), particularly ulnar nerve motor amplitudes, were reported.

The safety and efficacy of inotersen was also reported in ATTR-CM.100 Stabilisation of cardiac disease, as measured by left ventricular wall thickness and mass, as well as 6 min walk test and echocardiographic global longitudinal strain, was reported in patients with moderate-to-severe restrictive cardiomyopathy. An open-label trial is under way to assess tolerability and efficacy of inotersen in ATTR-CM (NCT03702829). As only a small fraction (<1%) of ASO cross the blood–brain barrier, inotersen is unlikely to have utility in leptomeningeal amyloidosis.

In order to improve the safety and dosing profile of inotersen, the ASO has been ligand-conjugated to allow hepatic receptor uptake.101 A phase I study (NCT03728634) has confirmed improved potency and safety of eplontersen (AKCEA-TTR-LRx), with no serious adverse events noted.102 Phase III studies are now under way in both ATTRv-PN (NCT04136184) and ATTR-CM (NCT04136171).

Small interfering RNAs

Gene expression can be modulated by siRNA (21–23 nucleotide long double-stranded RNA molecules) which target and cleaves complementary mRNAs. The siRNAs are synthetically produced and introduced into the cell, leading to ‘knockdown’ of target gene expression. Patisiran is a TTR-specific siRNA which has exhibited efficacy in preclinical and clinical studies. Targeting of the 3' untranslated region of TTR mRNA in primates resulted in 90% reduction of TTR at day 14 postinfusion and >70% reduction at day 28.102 A phase I study in mild–moderate ATTR-PN resulted in a dose-dependent reduction in serum TTR protein levels.102 The duration of suppression was greater with higher doses, while TTR knockdown observed in humans was identical to that seen in non-human primates.

The APOLLO trial established clinical efficacy of patisiran (0.3 mg/kg infused three times per week) in ATTRv.103 Improvement in mNIS7+ scores at 18 months was reported, with clinical effects evident 9 months after treatment initiation. The clinical benefits were evident irrespective of the degree of peripheral neuropathy and correlated with TTR protein reduction. Improvements in AN, quality of life, gait speed, nutritional status and cardiac function were also seen. Patisiran was safe with mild–moderate infusion-related reactions reported.

An open-label extension study reported sustained long-term clinical effectiveness of patisiran.104 Specifically, improvement in mNIS7+ was maintained at 12 months, as were improvements in AN, quality of life, nutritional status and overall disability. Switching from placebo to patisiran also resulted in an improvement or stabilisation of clinical parameters. No long-term safety issues were identified with patisiran treatment. The clinical benefits were evident across all measures of quality of life, including physical functioning, activities of daily living, and autonomic and small-fibre neuropathy symptoms, as well as pain perception.105

A second-generation siRNA (vutrisiran) is under investigation for treatment of ATTRv. Like patisiran, it contains an siRNA that targets a highly conserved mRNA sequence across all known TTR variants (including wild-type TTR).106 Subcutaneously administered vutrisiran (5–300 mg) led to a dose-dependent reduction in TTR, with mean TTR reduction varying between 57% and 97%.106 The reduction in TTR protein levels was maintained for ≥90 days post dose. The effectiveness of vutrisiran in ATTRv-PN and ATTR-CM is currently being investigated. Like ASOs, siRNAs do not efficiently cross the blood–brain barrier and hence are unlikely to have therapeutic utility in ATTR-LA.

Gene editing

An alternative to mRNA target-based gene silencing strategies is the use of clustered, regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR–Cas9) system to achieve in vivo gene editing. Given that ATTR is monogenic, and knockdown of TTR has limited physiological effects, CRISPR–Cas9-mediated in vivo gene editing would seem ideal for treatment of ATTRv. Additionally, TTR is largely produced by the liver for which established targeting systems (lipid nanoparticles (LNPs)) are available. NTLA-2001 (a novel CRISPR–Cas9-based gene-editing therapy) consists of a single-guide RNA (sgRNA) targeting human TTR with a human codon-optimised mRNA sequence of Streptococcus pyogenes (Spy)–Cas9 protein.107 The proprietary LNP enables targeted delivery of NTLA-2001 to hepatocytes by endocytosis through low-density lipoprotein receptors,108 and once in the cell, the Spy–Cas9 mRNA is translated to a Spy–Cas9 endonuclease, resulting in the formation of the Cas9–sgRNA ribonucleoprotein complex that enters into the nucleus and removes the mutant TTR gene.109 Intravenous infusion of NTLA-2001 was shown to reduce TTR protein levels by 95% after a single infusion in animal studies.107

A first-in-human study demonstrated a dose-dependent reduction of serum TTR protein levels in ATTRv-PN, after a single infusion of NTLA-2001.109 No serious adverse events were recorded, although three patients reported mild infusion related side effects. Further trials of CRISPR–Cas9-based therapeutic approaches are warranted to determine clinical efficacy and safety.

SUMMARY

This review outlines the recent advances in understanding of the pathogenesis, clinical phenotypes, diagnosis and treatment of ATTRv. Novel treatment strategies are revolutionising patient outcomes, underscoring the importance of early diagnosis. The ideal timing of treatment initiation, use of combination therapies, potential long-term complications of TTR depletion, and the treatment of sequestered leptomeningeal and ocular sites are issues that need to be further addressed. Recognition of the heterogeneous clinical presentations of amyloidosis and diagnostic strategies is essential for all clinicians, with the potential to greatly impact patient outcomes. It is likely that novel gene-editing therapies will herald a new era for treating protein misfolding diseases. Moreover, epigenetic factors and
mitochondrial polymorphism are additional areas that may be approached to modify disease outcomes.110

Author affiliations
1 Brain and Mind Centre, Faculty of Medicine and Health, Translational Research Collective, University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
2 Neurology, Mayo Clinic, Rochester, Minnesota, USA
3 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
4 Department of Neurosciences and Mental Health, Hospital de Santa Maria, Lisboa, Portugal
5 Northcott Neuroscience Laboratory, ANZAC Research Institute, Molecular Medicine Laboratory Concord Repatriation General Hospital, and Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia
6 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK
7 Bushell Chair of Neurology, Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia
8 Neurology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
9 Brain and Nerve Research Center, Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia

Twitter Matthew C Kiernan @jnnp_bmj

Contributors AC and SV planned the review and wrote the initial draft. PJD, Mdc, MK, MMR and MCK provided critical review, edited the manuscript and approved the final version.

Funding SV gratefully acknowledges funding support from the National Health and Medical Research Council (NHMRC) of Australia (project grant numbers 510233, 1024915 and 1055778; program grant number 1132524; dementia research team grant number 1095127; and Partnership Project number 1153439) and the Motor Neurone Disease Research Institute of Australia. MCK was supported by a NHMRC Practitioner Fellowship (number 1156093).

Competing interests Author MMR has consulted for Alyxlam, JIONS and AKCEA.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is

ORCID iDs
Antonia Carroll http://orcid.org/0000-0002-1738-9580
P James Dyck http://orcid.org/0000-0003-0212-8254
Matthew C Kiernan http://orcid.org/0000-0001-9054-026X
Steve Vucic http://orcid.org/0000-0002-8323-873X

REFERENCES
3 Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA 2020;324:79–89.


Neurol Genet 2021;7:145–53.


<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Study</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Outcome</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diflunisal</td>
<td>TTR tetramer stabiliser (NSAID)</td>
<td>NCT00292467 1 Phase 3 Double-blinded Placebo-controlled RCT N=130 1:1 allocation</td>
<td>250mg bd PO for 24 months (with PPI)</td>
<td>- 18-75y.o.</td>
<td>1°: 29.7% diflunisal vs. 9.4% placebo showed reduced rate of neurologic progression (NIS+7) and improved QoL (SF-36) over 2 years</td>
<td>Upper GIT ulceration and GORD Renal impairment Platelet aggregation inhibition and bleeding Hypertension Fluid retention Monitor FBC and EUC 3/12 PPI cover</td>
</tr>
<tr>
<td>Tafamidis (Vyndagel; Vyndamax)</td>
<td>TTR tetramer stabiliser</td>
<td>Fx-005 Phase 2/3 Double-blind Placebo-controlled RCT NCT0040917 5 N= 128 OLE- 30 months NCT0079149 2 N= 86</td>
<td>20mg PO daily for 18 months</td>
<td>- 18-75y.o.</td>
<td>Fx-005 - No difference in NIS-LL or NF-QoL-DN responder on IT - EE cohort:60% NIS-LL responders vs 38% placebo; improved NF-QoL-DN OLE - Stabilisation of NIS-LL and NF-QoL-DN - Rate of change of NIS-LL reduced in patients switching from placebo Tafamidis 30/12 56% greater preservation of NIS-LL than late initiation No difference in AE between Tafamidis and placebo No monitoring required</td>
<td></td>
</tr>
<tr>
<td>Tafamidis (free acid form)/ Vyndamax 61mg PO daily</td>
<td>- No known SE or interactions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tafamidis meglumine/ Vyndagel: 80mg daily or 20mg daily PO for 30 months</td>
<td>Note: Tafamidis (free acid form)/ Vyndamax 61mg PO daily</td>
<td>- 18-90 y.o.</td>
<td>- ATTCM (v and wt) - HF symptoms or prior hospitalisation - IVSd &gt;12mm - Biopsy or scintigraphy proven ATTR amyloidosis</td>
<td>1°: Tafamidis showed lower all-cause mortality vs placebo 29.5% vs 42.9% 2°: Cardiovascular-related hospitalisations were reduced RR of 0.68 (0.48 per year vs. 0.70 per year). Except in NYHA class III where hospitalisations &gt; placebo Reduced 6-MWT and KCCQ in Tafamidis vs controls NNT 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tafamidis (free acid form)/ Vyndamax 61mg PO daily</td>
<td>- 18-90 y.o.</td>
<td>- ATTCM (v and wt) - HF symptoms or prior hospitalisation - IVSd &gt;12mm - Biopsy or scintigraphy proven ATTR amyloidosis</td>
<td>1°: Tafamidis showed lower all-cause mortality vs placebo 29.5% vs 42.9% 2°: Cardiovascular-related hospitalisations were reduced RR of 0.68 (0.48 per year vs. 0.70 per year). Except in NYHA class III where hospitalisations &gt; placebo Reduced 6-MWT and KCCQ in Tafamidis vs controls NNT 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acoramadis (AG10/ ALXN2060)</td>
<td>TTR tetramer stabiliser</td>
<td>ATTRibute-CM NCT0386093 5 Phase 3 Double-</td>
<td>800mg PO bd for 30 months</td>
<td>- 18-90 y.o.</td>
<td>Estimated completion May 2023 1°: 6MWT at M12. Composite all-cause No known SE or interactions</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ATTR-ACT</th>
<th>NCT0199488 9 Phase 3, Double-blind, Placebo-controlled RCT N=441 2:1:2 allocation (80mg: 20mg: placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tafamidis</td>
<td>Estimated completion May 2023 1°: 6MWT at M12. Composite all-cause No known SE or interactions</td>
</tr>
</tbody>
</table>

Note: Tafamidis (free acid form)/ Vyndamax 61mg PO daily
<p>| <strong>Green Tea</strong> (EGCG) | <strong>TTR resorption</strong> | <strong>Case cohort</strong> N=25 | 600mg PO daily for up to 12 months | - ATTRwt&lt;br&gt; - Endomyocardial biopsy positive&lt;br&gt; - Gene testing negative | 1°: 12 out of 14 showed a decrease of 5.9% in left ventricular myocardial mass on cMR&lt;br&gt; Liver function derangement (rare liver failure).&lt;br&gt; Insomnia |
| <strong>Doxycycline</strong> and TUDCA | <strong>TTR synthesis inhibitor and TTR resorption</strong> | Phase 2, Single-centre, Open-label, non-randomised&lt;br&gt;NCT0117185&lt;br&gt;NCT0185536&lt;br&gt;N=40 | Doxycycline 100mg PO bd and TUDCA 250mg PO tds for 12 months | - &gt;18 y.o.&lt;br&gt; - ATTRwt and ATTRv&lt;br&gt; - Biopsy proven ATTR&lt;br&gt; - Symptomatic organ involvement&lt;br&gt; - ECOG-3&lt;br&gt; - NYHA&lt;3&lt;br&gt; - SBP&gt;100mmHg | Stable neuropathy in 46% (n=13 evaluable patients)&lt;br&gt; Stable NTproBNP in 75% (n=24 evaluable patients).&lt;br&gt; Doxycycline:&lt;br&gt; Photosensitive skin reactions&lt;br&gt; GIt side effects.&lt;br&gt; TUDCA: no significant AE |
| <strong>Inotersen</strong> (Tegsedi, IONIS-TTR Rx, ISIS 420915) | ASO Neuro-&lt;br&gt;NCT0173739&lt;br&gt;NCT01173739&lt;br&gt;NCT0173739&lt;br&gt;NCT0130282&lt;br&gt;NCT0130282&lt;br&gt;N=50 | 300mg SC x 3 in W1, followed by 300mg SC weekly for 16 months (+3000IU Vitamin A OD) | 1°: Improvement or non-progression in polyneuropathy (mNIS+7) 37% Inotersen vs 19% placebo.&lt;br&gt; Improvement or non-progression in NF-QoL-DN 50% vs 27% | SAE:&lt;br&gt; - Glomerulonephritis 3%&lt;br&gt; - Severe thrombocytopenia (&lt;25,000/mm^3) 3% including 1 death due to ICH due to grade 4 thrombocytopenia&lt;br&gt; - Thrombocytopenia (&lt;140,000/mm^3) in 54% vs 13% placebo&lt;br&gt; - Infusion/injection reactions Vitamin A Deficiency Monitor: EUC, FBC, Urine analysis 2 weekly&lt;br&gt; Supplement Vitamin A |
| <strong>Eplontersen</strong> | ASO Neuro-&lt;br&gt;NCT0370282&lt;br&gt;NCT0370282&lt;br&gt;N=50 | 300mg SC weekly for 24 months (+3000IU Vitamin A OD) | 1°: LV strain compared with baseline at M6&lt;br&gt; 2°: LV strain compared with baseline at M12, M18, M24, cMR extracellular volume at M6, M12, M24 | Estimated completion March 2022&lt;br&gt; 1°: LV strain compared with baseline at M6&lt;br&gt; 2°: LV strain compared with baseline at M12, M18, M24, cMR extracellular volume at M6, M12, M24&lt;br&gt; Estimated Vitamin A Deficiency |</p>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Type</th>
<th>Study</th>
<th>Phase</th>
<th>Design</th>
<th>Dosing</th>
<th>Primary Endpoints</th>
<th>Secondary Endpoints</th>
<th>N</th>
<th>Study Completion</th>
<th>Key Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiotoxin</td>
<td>siRNA</td>
<td>TTRTransform NCT01413618</td>
<td>4</td>
<td>Phase 3</td>
<td>Open-label Crossover study RCT N=168</td>
<td>every 4 weeks for 65 weeks (vs Inotersen SC weekly) (+3000IU Vitamin A OD)</td>
<td>- ATTRv-PN - Costantino I-2 - NIS 10-130</td>
<td>- ATTR-CM - Biopsy or Bone scintigraphy confirmed ATTR - NYHA I-III - IVSd &gt;12mm</td>
<td>Estimated completion Jan 2024</td>
<td>1°: Change in mNIS+7 and NF-QoL-DN at W66, change in TTR serum concentrations 2°: Change in mNIS+7, NF-QoL-DN at W35, SF-36, PND and mBMI at W65.</td>
</tr>
<tr>
<td>Cardio</td>
<td>siRNA</td>
<td>APOLLO NCT0196034</td>
<td>8</td>
<td>Phase 3</td>
<td>Double-Blinded Placebo-controlled RCT Ongoing enrolment estimated N=750</td>
<td>45mg SC every 4 weeks (+3000IU Vitamin A OD)</td>
<td>- 18-90 y.o. - ATTR-CM - Biopsy or Bone scintigraphy confirmed ATTR - NYHA I-III - IVSd &gt;12mm</td>
<td>- 1°: Composite of CV mortality and recurrent CV clinical events at M30 2°: Change in baseline 6MWT, KCCQ, CV mortality, CV events, All-cause mortality at M30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardio</td>
<td>siRNA</td>
<td>APOLLO-B NCT0399738</td>
<td>3</td>
<td>Phase 3</td>
<td>Double-Blinded Placebo-controlled RCT N=360</td>
<td>0.3mg/kg IVI, 3 weekly (max 30mg) for 18 months (+3000IU Vitamin A OD and infusion premedication s – IV steroid, paracetamol, H1- and H2-receptor blockers)</td>
<td>- 18-85 y.o. - ATTRv-PN - NIS: 5-130 - PND &lt;IIIb - NYHA&lt;3</td>
<td>1°: Improvement or less progression in polyneuropathy scores (mNIS+7) in 56% vs 4% 2°: Improvements in NF-QoL-DN, 10-MWT, NIS, mBMI, R-ODS and COMPASS31 scores.</td>
<td>Estimated completion June 2024</td>
<td></td>
</tr>
<tr>
<td>Vutisiran</td>
<td>siRNA conjugated to GaINAc</td>
<td>HELIOS-A NCT0375927</td>
<td>2</td>
<td>Phase 3</td>
<td>Open-label RCT N=164</td>
<td>25mg SC every 12 weeks (vs Patisiran IV and Placebo cohort from APOLLO) for 18 months (+ 3000 IU Vitamin A daily)</td>
<td>- 18-85 y.o. - ATTR-CM (v or wt) - HF symptoms or prior hospitalisation - Stable HF (no hospitalisation in 652) - Tafamidis naive, or progression on Tafamidis &gt;6/12 - &gt;150m on 6MWT - NTproBNP &gt;300ng/L and &lt;8500ng/L</td>
<td>1°: Change in mNIS+7 at 9 months 2°: Change in NF-QoL-DN, 10-MWT at M9, Change in m-NIS, NF-QoL-DN, 10-MWT, mBMI</td>
<td>Estimated completion May 2024</td>
<td>Mild-Mod AE - Injection site reactions Vitamin A Deficiency Supplement Vit A</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Design</th>
<th>N</th>
<th>Key Inclusion Criteria</th>
<th>Key Exclusion Criteria</th>
<th>Primary Outcomes</th>
<th>Secondary Outcomes</th>
<th>Estimated Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>HELIOS-B</td>
<td>R-ODS at M18 Interim 9/12 reporting: improved mNIS+7, NF QoL-DN, and stability of 10-MWT, NTproBNP c/w Placebo</td>
<td>Phase 3 Double-blinded, Placebo-controlled RCT N= 665</td>
<td>25mg SC every 12 weeks (+ 3000 IU Vitamin A daily)</td>
<td>18-85 y.o.</td>
<td>- ATTR-CM (v or wt) - HF symptoms or prior hospitalisation - &gt; 150m on 6MWT</td>
<td>NTproBNP c/w Placebo</td>
<td>Estimated completion June 2025</td>
<td>Outcome measures: 1: Composite outcome of all-cause mortality and recurrent CV hospitalisations at 30-36mo 2: Change in 6MWT, KCCQ score, LVWT, GLS, mortality, CV events, NTProBNP</td>
</tr>
<tr>
<td>CRISPR-Cas9 gene editing (NTLA-2001)</td>
<td>TTR gene editing</td>
<td>Phase 1 Open-label, single ascending dose followed by single dose expansion Ongoing recruitment N=74</td>
<td>0.1mg/kg and 0.3mg/kg single dose IV</td>
<td>18-80 y.o.</td>
<td>- ATTR-CM (v or wt) - NYHA I-III - HF symptoms or prior hospitalisation - &gt;150m on 6MWT</td>
<td></td>
<td>Estimated completion Nov 2024</td>
<td>Initial dosing groups n=6: - Durable knock out of TTR after single dose - 0.1mg/kg – 52% and 0.3mg/kg – 87% reduction in TTR concentration at D28</td>
</tr>
<tr>
<td>PRX-004 (monoclonal antibody to misfolded TTR)</td>
<td>Amyloid deposit clearance</td>
<td>Phase 1 Open-label Dose-escalation NCT0336580 N=21</td>
<td>IV every 28 days</td>
<td>&gt;18 y.o.</td>
<td>- ATTR biopsy, genetics, scintigraphy proven - KPS&gt;60% - NTproBNP &gt;650 and &lt;5000pg/mL or IVSd &gt;12mm</td>
<td></td>
<td>Terminated due to COVID Dose escalation study to determine safety, tolerability, PK and PD.</td>
<td>TBD</td>
</tr>
<tr>
<td>NE006 (monoclonal antibody to misfolded TTR)</td>
<td>Amyloid deposit clearance</td>
<td>Phase 1 Double-blinded, Placebo-controlled Dose-escalation RCT NCT0436043 N=36</td>
<td>IV every 28 days</td>
<td>&gt;18 y.o.</td>
<td>- ATTR-CM (v or wt) - LVED&gt;40mm, LVWT&gt;14mm, NTproBNP &gt;600pg/mL, 6MWT&gt;150m - Stability over 30days - KPS&gt;60%</td>
<td></td>
<td>Estimated completion June 2022</td>
<td>Dose escalation study to determine safety, tolerability, PK and PD.</td>
</tr>
<tr>
<td>Anti-SAP monoclonal antibody (Dezamizumab ) and CPHPC (Miridesap)</td>
<td>Deposit elimination</td>
<td>Phase 2 Open-Label Non-randomised NCT0444353 N=7</td>
<td>CPHPC 20mg/hr IV daily for 3 d then anti-SAP antibody D1 and D3 IV, with 60mg CPHPC SC TDS D1-11</td>
<td>18-80 y.o.</td>
<td>- ATTR-CM (v or wt) - biops, genetics, scintigraphy proven - LGE on cMR - LV Mass on cMR&gt; 200g - Stable NYHA 2-3</td>
<td></td>
<td>Study Terminated due to change in benefit/risk profile 1: Safety and efficacy, change in LV Mass</td>
<td>In Phase 1 (n=42; NCT01777243) self-limiting rash with higher doses</td>
</tr>
</tbody>
</table>
### Table 1: Clinical trials in ATTR amyloidosis.

Abbreviations: 6MWT = 6 minute walk test; 10-MWT = 10m walk test; ADL=activities of daily living, AE = adverse events; AN = Autonomic neuropathy; ASO= antisense oligonucleotide, ATTRv= variant (hereditary) transthyretin amyloidosis, bd = bi-daily; cMR = cardiac MRI; COMPASS-31 = Composite Autonomic Symptom Score; CV = cardiovascular; c/w = compared with; D = Day; ECOG = Eastern Cooperative Oncology Group; EUC = Kidney function test; EE = efficacy-evalutabe population; FBC= Full blood count; GalNAc = N-acetyl galactosamine; GIT = Gastrointestinal; GLS = Global longitudinal strain; GORD= gastro-oesophageal reflux disease; HF= Heart failure; IVI=intravenous infusion; IIT = intention to treat; IVSd = Interventricular septal diameter; KCCQ = Kansas City Cardiomyopathy questionnaire; KPS = Karnofsky Performance scale; LGE = Late gadolinium enhancement; LV = Left ventricular; LVEF = left ventricular ejection fraction; LVWT= Left-ventricular wall thickness; M = Month; mBMI = modified BMI; mNIS+7=modified Neuropathy Impairment Scale+7; N = number of participants; NF-QoL-DN= Norfolk Quality of Life-Diabetic Neuropathy questionnaire; NIS-LL= neuropathy Impairment Score lower limb subscale; NNT = number needed to treat; NSAID = non-steroidal anti-inflammatory drug; NYHA = New York Heart Association; OLE = Open-label extension; PD = Pharmacodynamics; PK = Pharmacokinetics; PN = Peripheral neuropathy; PND = polyneuropathy disability score; PO = per-oral; PPI = proton-pump inhibitor; QOL = quality of life; RCT= randomized controlled trial; R-ODS = Rasch-built overall disability scale; RR = relative risk; SAE= serious adverse events, SAP = serum amyloid P; SC = sub-cutaneous, SF-36 = 36-Item Short Form Health Survey; siRNA= small interfering RNA; TBD = To be determined; TDS = Three times daily; W = Week.